On September 18, 65, Dr Opas Karn Kawinpong The Director General of the Department of Disease Control said that the fact that Thailand has provided ready-made immunity or long-acting antibodies (LAAB) to people in need is considered an increase. the level of strengthening immunity against COVID-19 to be taken to care for and protect people’s health. especially for patients with low immunity The body is unable to develop immunity through vaccination. 608 risk groups, such as chronic renal failure patients undergoing dialysis. Organ or bone marrow transplanters receiving immunosuppressive drugs immunocompromised This group, if infected, may be at risk of severe disease or high probability of death. Immunological function, or LAAB, will help boost immunity in people who are less responsive to vaccines than the general population. Once injected, the body will build high immunity to the virus right after the injection. Make it very useful To reduce the risk of death in such patients. In foreign countries, LAAB has been registered for the use of immunosuppressants to treat vulnerable and vulnerable COVID patients, such as the United States, Japan.
In Thailand, LAAB immunosuppressants are imported and injected for the first time in patients with chronic renal failure undergoing dialysis. at the Bamrasnaradura Institute on 27 July 2022 and sent to various provinces Nationally from 1 August 2022, target groups in the early stages of patients with chronic renal failure in need of renal replacement therapy (dialysis) who have received organ transplants. Bone marrow transplant patients They can see a doctor to be considered for COVID-19 immunity boosting with LAAB or they can contact a hospital for injections. The policy was delivered to all the provincial ASLs. Investigate the number of eligible patients in all hospitals below in order for the target group to be completely immune from LAAB In addition, the Ministry of Public Health is considering adding target groups in need of immunization, such as cancer patients undergoing chemotherapy and radiotherapy , organ transplant patients requiring high-dose immunosuppressive therapy and people with cancer. and other immunocompromised patients
Dr. Opas added that In early September 2022, a 105-year-old COVID-19 patient and never vaccinated for COVID-19 was hospitalized on September 3, 2022 with high fever, sputum, oxygen. and later had a bacterial lung infection. This patient received antiretroviral therapy on the first day. But due to old age, the risk of death Doctors then consider giving patients ready immunotherapy (LAAB) on September 4, 2022, along with antibiotics. that from September 10, 2022, the patient’s symptoms gradually better in order Symptoms of lung infection decreased, fever decreased, blood oxygen returned to normal. and patients were able to go home on 14 September 2022, the total duration of treatment was less than 2 weeks. Immunotherapy (LAAB) is expected to be effective in treating elderly patients in the risk group without immunity. However, the Ministry of Public Health also points out that all seniors are recommended to get vaccinated against COVID as soon as possible before they become infected.
In this regard, self-protection against COVID-19 can be carried out according to the highest prevention measures for COVID-19, 2U, i.e. Universal Prevention, frequent hand washing, social distancing, wearing masks, the elderly, patients with 7 chronic illnesses and pregnant women avoid going places. Crowded and universal vaccination is vaccination against COVID-19, especially group 608 of other patients and their close caregivers. should take a booster needle When receiving the last dose at least 4 months or more because immunity will decline over time. If infected, it can become seriously ill. For more information, contact the Department of Disease Control Hotline, call 1422.
–
